Unnatural Products (UNP), a biotech innovator based in Santa Cruz, California, has raised $45 million in Series B financing to accelerate its work on macrocyclic peptide therapeutics. The investment will help propel UNP’s drug development platform, which aims to target diseases previously deemed undruggable by conventional therapies.
Key Takeaways
- UNP secured $45 million in Series B funding led by The Venture Collective, with notable participation from Merck Global Health Innovation Fund, argenx, Droia Ventures, and others.
- The capital will fuel the advancement of the company’s proprietary macrocyclic peptide drug discovery platform.
- Macrocyclic peptides promise to combine the selectivity of biologics with the convenience of oral delivery, targeting diseases currently treated via injection.
- The financing follows a major licensing deal with Novartis, potentially worth up to $1.7 billion.
Driving Macrocyclic Peptide Therapeutic Innovation
UNP’s technology centers around the engineering of synthetic macrocyclic peptides—complex molecules that can bind selectively to tough intracellular targets. Unlike many biotech drugs, macrocyclic peptides may penetrate cells and be taken orally, addressing weaknesses left by existing injectable biologics.
CEO Cameron Pye explained that the funding round was carefully structured to attract investors who understand both macrocyclic peptide science and drug development’s long-term demands. The backers bring not only capital, but strategic insights to help UNP’s programs move toward the clinic and open up new druggable targets.
A Platform Built for Scale and Precision
UNP’s platform uses cutting-edge computational design, automated chemistry, and high-throughput biological testing to reliably generate and optimize synthetic macrocyclic peptides. This integrated approach positions UNP to develop multiple new therapeutics across cardiometabolic, inflammatory, and immunological disease areas.
The platform’s strengths include:
- Automated Chemistry: Enables rapid synthesis of diverse molecules at scale.
- Computational Design: Utilizes machine learning to predict peptide activity and selectivity.
- High-Throughput Screening: Allows for fast biological evaluation and candidate optimization.
Strategic Partnerships and Future Pipeline
In addition to the new funding, UNP recently entered an expansive licensing agreement with pharmaceutical giant Novartis, focused on cardiovascular disease targets. The deal includes up to $100 million upfront and could total $1.7 billion upon hitting key development milestones.
UNP has also established collaborations with major industry players like Merck and BridgeBio. These partnerships are testament to the company’s growing reputation and the increasingly central role of macrocyclic peptides in drug discovery.
Why This Matters
Macrocyclic peptides are gaining momentum as a therapeutic class capable of overcoming the limitations of traditional small molecules and biologics. Their ability to address ‘undruggable’ targets could reshape treatment options for a variety of complex diseases, bringing new hope to patients requiring more accessible therapies.
As UNP advances its mission, the industry will watch closely to see if macrocyclic peptide drugs deliver on their transformative promise.
References
- UNP closes $45m Series B to advance macrocyclic peptides, BioXconomy.
- Unnatural Products Raises $45 Million Series B Financing to Advance Macrocyclic Peptide Therapeutics
| The Manila Times, The Manila Times. - After Novartis pact, macrocycle shop Unnatural Products gets $45M Series B, Endpoints News.
